QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

This study is testing an immunotherapy drug called QL1706 — which combines two immune checkpoint blockers into one — for people with advanced bone and soft tissue sarcomas. Sarcomas are rare cancers that develop in bones, muscles, fat, and connective tissues. The specific tumor types in this study include leiomyosarcoma, angiosarcoma, chordoma, alveolar soft part sarcoma, and several others. **You may be eligible if...** - You are between 18 and 75 years old - You have confirmed advanced or metastatic bone or soft tissue sarcoma of one of the specified subtypes - For most subtypes, you must have already received standard chemotherapy that stopped working - You have at least one measurable tumor - Your organ function is adequate **You may NOT be eligible if...** - You have received prior immunotherapy drugs targeting PD-1/PD-L1 (for certain subtypes) - Your blood counts, liver, kidney, or heart function is significantly impaired - You have active autoimmune disease or are on high-dose immunosuppressive therapy - Your general health is too poor to participate Talk to your doctor to see if this trial is right for you.